PT  - JOURNAL ARTICLE
AU  - Turner, A.M.
AU  - Li, L.
AU  - Monk, I.R.
AU  - Lee, J.Y.H.
AU  - Ingle, D.J.
AU  - Portelli, S.
AU  - Sherry, N.L.
AU  - Isles, N.
AU  - Seemann, T.
AU  - Sharkey, L.K.
AU  - Walsh, C.J.
AU  - Reid, G.E.
AU  - Nie, S.
AU  - Eijkelkamp, B.A.
AU  - Holmes, N.E.
AU  - Collis, B.
AU  - Vogrin, S.
AU  - Hiergeist, A.
AU  - Weber, D.
AU  - Gessner, A.
AU  - Holler, E.
AU  - Ascher, D.B.
AU  - Duchene, S.
AU  - Scott, N.E.
AU  - Stinear, T.P.
AU  - Kwong, J.C.
AU  - Gorrie, C.L.
AU  - Howden, B.P.
AU  - Carter, G.P.
TI  - Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
AID  - 10.1101/2023.03.01.23286614
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.03.01.23286614
4099  - http://medrxiv.org/content/early/2024/05/06/2023.03.01.23286614.short
4100  - http://medrxiv.org/content/early/2024/05/06/2023.03.01.23286614.full
AB  - Multidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode-of-action, but for which resistance has surprisingly been widely reported but unexplained. Here we show that rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in liver disease patients, causes cross-resistance to daptomycin in VREfm. Amino acid changes arising within the bacterial RNA polymerase in response to rifaximin exposure cause upregulation of a previously uncharacterised operon (prdRAB) that leads to cell membrane remodelling and cross-resistance to daptomycin through reduced binding of the antibiotic. Alarmingly, VREfm with these mutations are spread globally, making this a major mechanism of resistance. Rifaximin has been considered ‘low-risk’ for antibiotic resistance development. Our study shows this assumption is flawed and widespread rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin, a major last-resort intervention for multidrug-resistant pathogens. These findings demonstrate how unanticipated antibiotic cross-resistance can undermine global strategies designed to preserve the clinical use of critical antibiotics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Health and Medical Research Council (NHMRC) of Australia (GNT1185213 and GNT1160745). BPH is supported by an NHMRC Investigator Grant (GNT1196103). JCK is supported by an NHMRC Early Career Fellowship (GNT1142613). AMT and NLS are supported by an Australian Government Research Training Program scholarship. DJI is supported by an NHMRC Investigator Grant (GNT1195210). SD is supported by the Australian Research Council (DE190100805). The Controlling Superbugs study was supported by the Melbourne Genomics Health Alliance (funded by the State Government of Victoria, Department of Health and Human Services, and the 10 member organizations). NES is supported by an Australian Research Council Future Fellowship (FT200100270) and an ARC Discovery Project Grant (DP210100362). We thank the Melbourne Mass Spectrometry and Proteomics Facility of The Bio21 Molecular Science and Biotechnology Institute for access to MS instrumentation and staff within the Microbiological Diagnostic Unit Public Health Laboratory for technical assistance with antimicrobial susceptibility testing and whole genome sequencing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were obtained from medical records with approval from the local Human Research Ethics Committee (HREC/92972/Austin-2023).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data presented in the study are deposited under Bioprojects PRJNA565795, PRJNA433676, PRJNA856406, and PRJNA856406.